Urelumab

Drug Profile

Urelumab

Alternative Names: Anti-CD137 monoclonal antibody - Medarex/Bristol-Myers Squibb; BMS-663513; BMS-66513

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Colorectal cancer; Glioblastoma; Head and neck cancer; Multiple myeloma
  • No development reported Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 14 Dec 2016 Bristol-Myers Squibb completes a phase I trial in Head and neck cancer and colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT02110082)
  • 05 Dec 2016 M.D. Anderson Cancer Center withdraws a phase-II clinical trial for Chronic lymphocytic leukaemia prior to enrolment in USA (IV) (NCT02420938)
  • 12 Nov 2016 Efficacy and adverse events data in phase-I/II trial in Haematologic and solid tumours released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top